AIM ImmunoTech (NYSEMKT:AIM) +45% pre-market after saying it has joined with ChinaGoAbroad to facilitate the entry of its experimental drug Ampligen into China for use as an early-onset therapeutic against COVID-19.
ChinaGoAbroad is a member-based online information
platform serving to facilitate two-way international transactions in
collaboration with the China Overseas Development Association.
AIM says Ampligen achieved a 100% survival rate in
SARS animal experiments after the 2003 outbreak, and it believes the
drug may provide similarly effective prophylaxis against COVID-19.
https://seekingalpha.com/news/3546517-aim-immunotech-gets-china-entry-boost-for-coronavirus-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.